The clinical prognostic ability of these three genes was validated in the TCGA cohort, where high expression of COQ2 and MPC1 was associated with better prognosis for CRC patients, while high expression of ADAMTS13 was associated with worse prognosis. Here, COQ2 is linked to colorectal carcinoma.